Date
- Friday, 23 November 2018, All day
Location
- European Medicines Agency, Amsterdam, the Netherlands
This is the fourth in a series of regular meetings between regulators and representatives of industry stakeholder organisations, hosted by the European Medicines Agency (EMA). It addresses all areas of product-development support, from scientific advice, through specifics for paediatric and orphan medicines, to innovation support.
This meeting will focus on the future regulation of integrated drug-device combinations, experience with the qualification of digital technology proposals, current challenges in developments with biomarkers and opportunities for 'post-licensing evidence generation' proposals in scientific advice. It will also provide updates on activities on:
- next generation sequencing;
- Parallel consultation with regulators and health technology assessment bodies;
- orphan designation reviews;
- topics from the European Medicines Agency and European Commission (DG Health and Food Safety) action plan on paediatrics